Use of lactiflorin in preparation of drug for treating inflammatory bowel disease

By developing peony root and its combination with mesalazine, the problem of targeting PPAR-γ and inhibiting cell pyroptosis in the treatment of ulcerative colitis was solved, and the efficacy and safety of ulcerative colitis was significantly improved. , new treatment options are provided.

WO2024230522A1PCT designated stage expired Publication Date: 2024-11-14ANHUI ZHIBOJIAN BIOLOGICAL MEDICINE TECHNOLOGY CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/090244
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-11
Filing Date
2024-04-27
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

The existing treatment drugs for ulcerative colitis are ineffective in some patients, and the pathogenesis is complex, and there is a lack of effective target drugs, especially the strategies to inhibit pyroptosis.

Method used

Develop peonyoside as a new active ingredient, maintains the integrity of the colon mucosal barrier by inhibiting inflammation-induced pyroptosis of colonic epithelial cells, and cooperates with mesalazine to target PPAR-γ activation to treat ulcers. Sexual colitis.

Benefits of technology

Paeoniaceae significantly improves colon damage in animal models of ulcerative colitis, has a much better efficacy than Paeoniaceae, is highly safe, has superior pharmacokinetic characteristics, and has synergistic effects with mesalazine complex, providing new Effective treatment method.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024090244_14112024_PF_FP_ABST
    Figure CN2024090244_14112024_PF_FP_ABST
Patent Text Reader

Abstract

Use of lactiflorin in the preparation of a drug for treating ulcerative colitis. Research finds that lactiflorin has a therapeutic effect on ulcerative colitis, and can significantly inhibit inflammation-induced pyroptosis of colon epithelial cells. Further experiments show that the specific mechanism of lactiflorin for inhibiting the pyroptosis of colon epithelial cells is to activate a peroxisome proliferator activated receptor γ-related signaling pathway. Therefore, lactiflorin can significantly reduce the intestinal injury in a DSS-induced colitis animal model, is a potential drug for treating inflammatory diseases such as ulcerative colitis, and provides a new drug selection for the treatment of patients with inflammatory bowel disease. In addition, lactiflorin has the advantages of wide drug sources, clear components and dosage, being safe to administer and no obvious side effects.
Need to check novelty before this filing date? Find Prior Art

Description

Application of paeoniflorin in preparing medicine for treating inflammatory bowel disease Technical Field

[0001] The invention belongs to the technical field of traditional Chinese medicine, and specifically relates to the application of paeoniflorin in the preparation of a medicine for treating ulcerative colitis. Background Art

[0002] Inflammatory bowel disease (IBD), an autoimmune disease, continues to rise in incidence worldwide. Ulcerative colitis (UC), one of the major types of IBD, is a chronic, relapsing inflammatory disease characterized by mucosal epithelial damage and intestinal flora disturbances. Although various studies have reported that genetic background, environmental factors, and immune dysfunction contribute to the pathogenesis of UC, the precise mechanisms underlying its occurrence and progression remain to be fully elucidated. Furthermore, UC patients often experience varying degrees of inflammation in extraintestinal tissues (liver, lungs, skin, eyes, joints, and vascular system). In addition, UC patients also have a higher risk of colorectal cancer (Wei YY, Fan YM, Ga Y, Zhang YN, Han JC, Hao ZH. Shaoyao decoction attenuates DSS-induced ulcerative colitis, macrophage and NLRP3 inflammasome activation through the MKP1 / NF-κB pathway. Phytomedicine. 2021 Nov; 92: 153743.).

[0003] Before 2000, treatment options for ulcerative colitis (UC) were limited to corticosteroids, aminosalicylic acids, thiopurines, and calcineurin inhibitors. After 2000, biologic therapies targeting tumor necrosis factor (TNF) were introduced for the treatment of UC, and subsequently, other molecules targeting different biological pathways were introduced into clinical treatment for UC (Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis 2017;11:769–84.). Just 20 years after infliximab was approved for UC by the European Medicines Agency and the US Food and Drug Administration, three classes of biologic therapies (anti-TNF-α, anti-integrin, and interleukin inhibitors [IL-12 and IL-23]) and the first small molecules (Janus kinase inhibitors) were approved for the treatment of moderate to severe ulcerative colitis. In addition, new drugs from these and other classes (such as sphingosine 1-phosphate receptor 1 [S1P1] modulators) will soon enter preclinical studies and obtain positive data from phase 3 clinical trials (Sabino J, Verstockt B, Vermeire S, Ferrante M. New biologics and small molecules in inflammatory bowel disease: an update. Therap Adv Gastroenterol 2019;12:1756284819853208.).

[0004] Despite recent progress in the treatment of UC, it is common for some patients to be unresponsive to current UC medications, leaving a significant number of patients without available treatment options. Therefore, developing new targeted drugs is a key concern for researchers.

[0005] The pathogenesis of ulcerative colitis (UC) is complex. Innate immunity is the first line of defense for recognizing infection and initiating pathogen clearance and tissue repair. A key player in this process is the NOD-like receptor thermal protein domain-associated protein 3 (NLRP3) inflammasome. This inflammasome leads to the proteolytic activation of the downstream cysteine ​​aspartate specific proteinase (Caspase-1), triggering the activation of the pore-forming protein gasdermin D (GSDMD) and the activation and secretion of the proinflammatory cytokines IL-1β and IL-18. Numerous clinical studies have demonstrated that IL-1β secretion by colonic tissue and macrophages is closely correlated with the severity of UC. Furthermore, preclinical studies have also demonstrated that IL-18 is also a key pathogenic factor in UC (Zhen Y, Zhang H. NLRP3 Inflammasome and Inflammatory Bowel Disease. Front Immunol. 2019 Feb 28;10:276). Cell pyroptosis is an important molecular mechanism in the occurrence and development of UC. Inhibiting cell pyroptosis, especially inhibiting intestinal epithelial cell pyroptosis, will become an effective strategy for the treatment of UC.

[0006] According to literature reports, PPARγ expression is significantly reduced in the intestinal mucosa of UC patients (Cao H, Liu J, Shen P, Cai J, Han Y, Zhu K, Fu Y, Zhang N, Zhang Z, Cao Y. Protective Effect of Naringin on DSS-Induced Ulcerative Colitis in Mice. J Agric Food Chem. 2018 Dec 19; 66(50): 13133-13140.). PPARγ activation increases the antioxidant and anti-inflammatory functions of cells. PPARγ activation can inhibit M1 polarization of macrophages and activation of dendritic cells. In addition, activation of PPARγ can reduce the occurrence of cell pyroptosis by inhibiting the activity of nuclear factor kappa-B (NF-κB) (Liu J, Yao Q, Xie X, Cui Q, Jiang T, Zhao Z, Du X, Lai B, Xiao L, Wang N. Procyanidin B2 Attenuates Nicotine-Induced Hepatocyte Pyroptosis through a PPARγ-Dependent Mechanism. Nutrients. 2022 Apr 22; 14(9): 1756.). Another study pointed out that PPARγ inhibits the activation of NLRP3 inflammasome by binding to NLRP3, disrupting the assembly of NLRP3 inflammasome complex, which may be another mechanism by which PPARγ inhibits cell pyroptosis (Liu J, Yao Q, Xie X, Cui Q, Jiang T, Zhao Z, Du X, Lai B, Xiao L, Wang N. Procyanidin B2 Attenuates Nicotine-Induced Hepatocyte Pyroptosis through a PPARγ-Dependent Mechanism. Nutrients. 2022 Apr 22; 14(9): 1756.).It is worth noting that PPARγ can also induce the expression of programmed death ligand-1 (PD-L1) in microsatellite-stable colorectal cancer cells, and PPARγ agonists can enhance the killing effect of lymphokine-activated killer cells and significantly inhibit the proliferation and survival of colorectal cancer cells (Gutting T, Hauber V, Pahl J, Klapproth K, Wu W, Dobrota I, Herweck F, Reichling J, Helm L, Schroeder T, Li B, Weidner P, Zhan T, Eckardt M, Betge J, Belle S, Sticht C, Gaiser T, Boutros M, Ebert MPA, Cerwenka A, Burgermeister E. PPARγinduces PD-L1 expression in MSS+colorectal cancer cells. Oncoimmunology. 2021 May 5; 10(1): 1906500.). This suggests that PPARγ agonists can not only treat UC, but may also have a preventive effect on colon cancer.

[0007] Experimental studies and clinical applications have shown that Shaoyao Decoction (Shaoyao Tang) has therapeutic effects on ulcerative colitis (UC), suggesting that peony contains one or more active ingredients that can treat ulcerative colitis. The active ingredients of peony were analyzed using the TCMSP (Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (tcmsp-e.com)) database. Using the screening criteria of oral availability > 40%, drug-like properties > 0.6, and water partition coefficient < 0, the active substances identified were paeoniflorin (Pae) ​​and lactiflorin (Lac). Paeoniflorin, the most abundant component in peony, has been extensively studied for its pharmacological effects. At present, a small number of literatures have reported the therapeutic effects of paeoniflorin on UC (Zheng K, Jia J, Yan S, Shen H, Zhu P, Yu J. Paeoniflorin ameliorates ulcerative colitis by modulating the dendritic cell-mediated TH17 / Treg balance. Inflammopharmacology. 2020 Dec; 28(6): 1705-1716.; Lu P, Herdtweck E, Bach T. Intramolecular [2+2] photocycloaddition reactions as an entry to the 2-oxatricyclo [4.2.1.0 (4,9)] nonan-3-one skeleton of lactiflorin. Chem Asian J. 2012 Aug; 7(8): 1947-58.). Paeoniflorin, one of the active ingredients from the natural plant Paeonia lactiflora, has been reported for its plant extraction and total synthesis (Gu P, Zhu L, Liu Y, Zhang L, Liu J, Shen H. Protective effects of paeoniflorin on TNBS-induced ulcerative colitis through inhibiting NF-kappaB pathway and apoptosis in mice. Int Immunopharmacol. 2017 Sep;50:152-160.). However, its pharmacological effects have been largely understudied. Structural analysis indicates that paeoniflorin is less polar than paeoniflorin, has better water solubility, and exhibits improved bioavailability.

[0008] Summary of the Invention

[0009] Based on prior art, the main active ingredient in Shaoyao Decoction for the treatment of ulcerative colitis is paeoniflorin. However, whether paeoniflorin, a structural analog of paeoniflorin and the main active ingredient in peony root, also exhibits similar or even stronger therapeutic effects as paeoniflorin remains unknown. Therefore, the present invention investigated the toxicology, pharmacokinetics, and pharmacodynamics of paeoniflorin and compared it with paeoniflorin. It was found that paeoniflorin and paeoniflorin are both safe and effective drugs, with paeoniflorin exhibiting better pharmacokinetic characteristics and greater drug development potential. Most importantly, in pharmacodynamic studies of the treatment of ulcerative colitis, paeoniflorin demonstrated far superior efficacy compared to paeoniflorin. Paeoniflorin significantly inhibits inflammation-induced pyroptosis of colonic epithelial cells and maintains the integrity of the colonic mucosal barrier, making it a potential drug for the treatment of ulcerative colitis. Further studies have revealed that paeoniflorin exhibits synergistic effects when combined with mesalazine. Consequently, the present invention addresses the gap in pharmacological research on paeoniflorin and provides an effective treatment for UC.

[0010] The present invention first explored the toxicological and pharmacokinetic data of paeoniflorin, then used a DSS-induced UC animal model to verify the therapeutic efficacy of paeoniflorin; and then used in vitro electron microscopy, molecular docking, protein immunoblotting and other techniques to reveal the molecular mechanism of paeoniflorin.

[0011] Based on this, the present invention aims to provide the use of paeoniflorin in the preparation of a medicament for treating ulcerative colitis (UC). It is mainly used to treat UC, an inflammatory immune disease, with the core therapeutic effect of inhibiting colonic epithelial cell pyroptosis and maintaining the integrity of the colonic mucosal barrier.

[0012] The present invention provides a novel paeoniflorin, or a use of a novel paeoniflorin compounded with mesalazine in preparing a medicament for treating inflammatory bowel disease, wherein the inflammatory bowel disease is ulcerative colitis.

[0013] Specifically, the medicament is used to alleviate inflammation-induced colon damage.

[0014] More specifically, the drug is used to inhibit pyroptosis of colonic epithelial cells. Furthermore, the drug is used to regulate the expression of PPAR-γ in colonic epithelial cells. In particular, the drug is used to target and activate PPAR-γ.

[0015] Preferably, the drug comprises paeoniflorin and a pharmaceutically acceptable excipient, and the dosage of the paeoniflorin is 4 mg / kg-7 mg / kg for human administration, preferably 4.17 mg / kg-6.84 mg / kg for human administration. When paeoniflorin is compounded with mesalazine, the ratio of the two is 0.8-1.2:1, preferably 1:1, which has a significant synergistic effect.

[0016] More specifically, the dosage form of the drug is granules, capsules, tablets, solutions, pills, or powders.

[0017] The present invention provides a novel paeoniflorin, or a combination of a novel paeoniflorin and mesalazine, which has a synergistic effect in alleviating inflammation-induced colon damage and is used in the preparation of a drug for inhibiting colon epithelial cell pyroptosis.

[0018] The present invention further provides the use of paeoniflorin or a combination of paeoniflorin and mesalazine in the preparation of a drug for regulating the expression of PPAR-γ in colonic epithelium.

[0019] The present invention also provides the use of paeoniflorin or a combination of paeoniflorin and mesalazine in the preparation of a drug that targets PPAR-γ protein and activates PPAR-γ.

[0020] Compared with existing technologies, the present invention offers the following advantages: The present invention selects highly effective active monomers from Shaoyao Decoction, a traditional Chinese medicine decoction effective for treating UC, and compares their efficacy with the most abundant component in Shaoyao Decoction, ensuring the high efficacy of the selected active monomers. Toxicology, pharmacokinetic, and pharmacodynamic experiments demonstrate that the present invention's new paeoniflorin is highly effective, well-absorbed, and highly safe. Furthermore, the monomers of the new paeoniflorin can be obtained through both total synthesis and plant extraction, providing flexible raw material acquisition.

[0021] The results of molecular biology experiments show that paeoniflorin, as a naturally derived active small molecule, may have multiple active targets, but its inhibitory effect on intestinal epithelial cell pyroptosis is extremely significant and has a definite therapeutic effect.

[0022] In summary, the present invention innovatively discovered that paeoniflorin can effectively protect the integrity of the colon mucosa of DSS-induced UC animals, reduce the damage of DSS to colon tissue, and maintain the health of model mice. At the same time, the present invention innovatively discovered that paeoniflorin significantly improved the structural and functional integrity of colon epithelial cells and inhibited the occurrence of inflammation-induced colon epithelial cell pyroptosis. The present invention also explored the mechanism of action and key targets of paeoniflorin, proving that the therapeutic effect of paeoniflorin is somewhat PPARγ-dependent. Therefore, paeoniflorin can significantly improve colon damage in UC animals and can be used clinically to treat UC. The present invention provides a new medication option for the treatment of UC patients, and the drug has a wide source, clear ingredients and dosage, and is safe to use without obvious side effects. Further studies have found that paeoniflorin has a synergistic effect when combined with mesalazine, and its application value is even greater. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1. Overview of the DSS-induced experimental colitis model in mice and the effects of Lac. A: Body weight fluctuation curve; B: Disease activity index (**P < 0.01 DSS vs. Control, ##P < 0.01 Lac (20 mg) vs. DSS, Mean ± SD, n = 5).

[0024] Figure 2. Representative images of colon damage in mice in each group.

[0025] Figure 3. Electron microscope image of HT-29.

[0026] Figure 4. Western blot bands of GSDMD-N.

[0027] Figure 5. Grayscale value statistics of GSDMD-N protein immunoblot bands. (***P<0.001DSS vs. Control group; ###P<0.001DSS vs. LPS+ATP group)

[0028] Figure 6. Molecular docking results of paeoniflorin and 1ZGY (PPARγ).

[0029] Figure 7. Western blotting bands showing the effects of paeoniflorin on the expression of PPAR-γ and GSDMD-N in HT-29 cells.

[0030] Figure 8. Grayscale statistical graphs of PPAR-γ and GSDMD-N protein immunoblot bands. (*P<0.05 LPS+ATP vs. Control group; #P<0.05 LPS+ATP+Lac vs. LPS+ATP group; $P<0.05, $$P<0.01 LPS+ATP+siRNA(PPAR-γ) vs. Control group; &P<0.05, &&P<0.01 LPS+ATP+siRNA(PPAR-γ)+Lac vs. Control group). DETAILED DESCRIPTION

[0031] The present invention will be further described in detail below through examples. However, this should not be construed as limiting the scope of the present invention to the following examples. All technologies implemented based on the above content of the present invention fall within the scope of the present invention.

[0032] Example 1: Study on acute toxicity of new peony glycosides

[0033] Kunming mice were administered a single oral gavage of 3g / kg or a single intravenous injection of 600mg / kg of paeoniflorin and observed twice daily for two weeks without mortality. During the observation period, no piloerection, changes in body color, normal movement, spasms, ataxia, or convulsions were observed in the gavage and caudal vein administration groups. Reflexes were normal, fur was smooth, and there were no abnormal discharges from the eyes, nose, or mouth. Feces and urine were normal compared to the control group. Ocular examination findings, such as no significant constriction, dilation, or proptosis, were all normal. No mice died in any of the groups during the 14-day observation period. Body weight was measured before dosing and on days 1, 3, 5, 7, 9, 11, and 14 after dosing. The mice showed varying degrees of weight gain with increasing feeding time, with no significant abnormalities observed. At the end of the observation period, the mice were sacrificed and autopsied. Gross examination revealed no significant abnormalities in major organs, including the heart, liver, spleen, lungs, and kidneys, in the gavage and caudal vein administration groups. The main histopathological staining results showed that the cell structure and morphology of the liver lobules in the drug-treated group were normal, without lesions or abnormalities, and the germinal center, marginal zone and red and white pulp junction in the spleen were normal. At the same time, the spleen tissue structure in the drug-treated group was basically the same as that in the control group, the lung tissue structure was clear, without edema and effusion, the alveolar structure was normal, the alveolar septa were slender and not widened, and the glomerular and renal unit cell structures were normal.

[0034] Example 2: Pharmacokinetic Study of Paeoniflorin and Neobiflorin by Single Oral Administration

[0035] According to three dosages (25 mg·kg -1 , 50mg·kg -1 , 100mg·kg-1 Mice were gavaged with paeoniflorin. Blood was then collected at 5, 10, 30, 45, 60, 90, 120, 240, and 360 minutes before and after administration. Plasma samples were processed and analyzed using UPLC-MS. The chromatographic peak areas at each time point in each group were measured and converted into plasma drug concentrations. Compartmental model analysis was performed using DAS (Drug and Statistics for Windows) ver 2.0 software, and pharmacokinetic parameters were calculated. The main pharmacokinetic parameters are shown in Tables 1 and 2. The calculated oral absolute bioavailability of paeoniflorin was approximately 49%, consistent with the results recorded in the TCMSP database. As shown in Tables 1 and 2, paeoniflorin is rapidly absorbed, has a good absorption rate, and is widely distributed in the body.

[0036] Table 1 Pharmacokinetic parameters of new paeoniflorin and paeoniflorin after single oral gavage in mice ( n=5)

[0037] Table 2 Pharmacokinetic parameters of new paeoniflorin and paeoniflorin after single intravenous injection in mice ( n=5)

[0038] Example 3: Effects of paeoniflorin on DSS-induced colitis model in mice

[0039] Sixty male C57BL / 6 mice, weighing 20 ± 2 g, were used for the experiment. All mice, except the control group, were given DSS solution ad libitum for one week. The control group drank water as a control. After one week, the mice were assessed for disease activity score (DAI), mass loss (%), stool characteristics, and blood in stool, reflecting the degree of inflammation. Ten days later, the mice were sacrificed by cervical dislocation. Colonic tissue was removed, cleaned, and its length was measured. The degree of colonic erosion was also observed.

[0040] The experimental animals were randomly divided into 9 groups: normal group, model group, positive control group, paeoniflorin group (25, 50, 100 mg kg -1 ), paeoniflorin groups (25, 50, 100 mg·kg -1). Medication regimen: Starting from 5 days before modeling, different doses of drugs were administered orally at a volume of 0.1 ml / 10 g, once a day for 5 consecutive days. The normal group and the model group were given corresponding volumes of sodium carboxymethyl cellulose (CMC-Na). The experimental results are shown in Figures 1 and 2. Compared with the model group, the positive control drug sulfasalazine (SASP) group and the lactiflorin (Lac) dose groups had a significant inhibitory effect on DSS-induced colon inflammation. The medium-dose and high-dose groups of paeoniflorin (Pae) ​​also improved the symptoms of colitis to a certain extent. Compared with the positive control drug group, the mice in the paeoniflorin group were in better condition, showing a certain degree of superiority.

[0041] During the entire experimental period, all mice in the modeling groups showed varying degrees of reduced activity, lethargy, dull fur, and bloody stools around the anus. In this experiment, the mice in the DSS group showed significant weight loss as early as the third day after the start of the modeling. By the end of the seventh day, the average weight loss of each mouse was nearly 20% of the basal body weight. The DSS group mice were able to detect positive fecal occult blood on the second day of the experiment, accompanied by changes in fecal characteristics such as soft stools. By the fifth day, all mice in the DSS group showed signs of ulcerative colitis such as gross bloody stools. The changes in the mice in the paeoniflorin group were not obvious, and were close to those in the control group. At the same time, the pus and bloody stool symptoms of the mice in the paeoniflorin group appeared later and were milder. After the completion of the experiment, the disease activity score and weight records were recorded, and the weight change curve and disease activity score curve were drawn (Figure 1).

[0042] After the experiment, the colons of mice in each group were dissected and extracted (from the cecum to the anus). After measurement and comparison with the control group, the colons of the experimental group mice were shortened to varying degrees, the intestinal wall was thickened, and elasticity was lost. When the intestinal cavity was opened, obvious intestinal mucosal erosion and bleeding were observed, and ulcers of varying areas were formed. The colon damage of the mice in the paeoniflorin group was also more serious. The degree of colon shortening of the mice in the new paeoniflorin group was less (Figure 2), and intestinal bleeding was not obvious. In terms of the morphology of intestinal mucosal ulcers, the mice in the DSS group showed continuous large-area mucosal ulcers, while the mice in the new paeoniflorin group showed scattered intestinal mucosal erythema or superficial ulcers.

[0043] Example 4: Effects of paeoniflorin on pyroptosis of intestinal epithelial cells

[0044] (1) HT-29 cell line was purchased from Wuhan Punosai Life Science Technology Co., Ltd. and HT-29 cell suspension (1×10 7 / ml), spread on 24-well culture plates, and slides were added to each well. 40 μl of HT-29 cell suspension (final concentration of 5×10 5 / ml) and 460μl complete culture medium, LPS (24 hours in advance) + ATP (1 hour in advance) were given in vitro to induce pyroptosis of colon epithelial cells, and paeoniflorin (10 -6 Mol / L, 20 hours in advance) and paeoniflorin (10 -6 Mol / L, 20 hours in advance). Then, the cells in each group were dehydrated, specifically 35% ethanol (10 minutes) - 50 ethanol (10 minutes) - 75% ethanol (10 minutes) - 95% ethanol (10 minutes, 2 times) - anhydrous ethanol (10 minutes, 2 times) - a mixture of hexamethylenediamine carbamate and anhydrous ethanol (1:2) for 20 minutes - a mixture of hexamethylenediamine carbamate and anhydrous ethanol (2:1) for 20 minutes - hexamethylenediamine carbamate (20 minutes, 2 times), and then air-dried in a fume hood. They were sent to the Electron Microscopy Center of Anhui Medical University for gold plating and photography, and the results are shown in Figure 3. The results of scanning electron microscopy showed that under the action of LPS+ATP, colonic epithelial cells lost their inherent morphology, became round, and the cell membranes were often ruptured. The pyroptosis characteristics of colonic epithelial cells in the paeoniflorin group were weakened, but it only delayed the process of cell pyroptosis. The cell membrane of colon epithelial cells in the paeoniflorin group was intact and the structure was three-dimensional, and basically no morphological characteristics of pyroptosis were observed, which was similar to that of the control group.

[0045] (2) Protein was extracted from cells treated with different methods, and then the expression levels of GSDMD-N in HT-29 cells treated with different methods were detected by Western blot. The results are shown in Figure 4. The results of Western blot showed that LPS and ATP treatment of colon epithelial cells could significantly upregulate the expression level of pyroptosis marker protein GSDMD-N, and paeoniflorin could reverse this upregulation. In contrast, paeoniflorin had a weaker effect in this regard, even close to no effect.

[0046] Example 5: Effect of paeoniflorin on PPARγ function in intestinal epithelial cells

[0047] (1) Molecular docking experiments showed that paeoniflorin has a strong affinity with PPAR-γ:

[0048] The Discovery Studio 2.1 (DS2.1; Accelrys Software Inc.) program was used to perform docking simulations of paeoniflorin and PPAR-γ protein (PDB ID: 1ZGY). The C-DOCKER algorithm module based on molecular dynamics (MD) simulated annealing in DS2.1 was used to define a 10° active site and a sphere based on the important amino acid residues of PPAR-γ generated around the active site pocket of the BSAI model. As mentioned above, the structures of the protein and substrate were energy minimized in DS2.1 using the chemical method of the Harvard University macromolecular mechanics force field, followed by full potential final minimization. Based on C-DOCKER, the energy docking conformation of the substrate was retrieved for post-docking analysis. Molecular docking experiments showed that the intermolecular interactions between paeoniflorin and PPAR-γ, such as hydrogen bonds and van der Waals forces, were strong. As shown in Figure 5, paeoniflorin has a strong affinity for PPAR-γ.

[0049] (2) Small interference experiments verified the PPAR-γ dependence of the therapeutic effect of paeoniflorin. As shown in Figure 6:

[0050] When HT-29 cells reached a density of 50-60%, they were transfected with siRNA-PPARγ or an empty vector using Lipofectamine 3000 according to the manufacturer's protocol. Total cell protein was extracted, and the expression of PPAR-γ and GSDMD-N was analyzed by Western blot, using β-actin as an internal control. As shown in Figure 6, GSDMD-N expression was significantly increased in the LPS + ATP + siRNA-PPARγ group. In the LPS + ATP + siRNA-PPARγ + Lac group, the inhibitory effect of Lac on pyroptosis was almost abolished, while GSDMD-N expression was increased. Small interference experiments confirmed that the therapeutic effects of paeoniflorin were PPAR-γ-dependent.

[0051] According to the results of protein immunoblotting, paeoniflorin inhibited the pyroptosis of HT-29 cells induced by LPS+ATP, but this inhibitory effect was PPAR-γ dependent.

[0052] The above results indicate that paeoniflorin can significantly improve colon damage in animal models of ulcerative colitis and can be used to treat ulcerative colitis.

[0053] Example 6: The effect of the combination of paeoniflorin and mesalazine.

[0054] An LPS-induced HT-29 cell inflammation model was established to study the effects of paeoniflorin, mesalazine, and their combination on the LPS-induced secretion of inflammatory mediators NO, COX-2, and PGE. First, the Dm concentration (median concentration) of paeoniflorin and mesalazine alone and in combination on the inflammatory mediators NO, COX-2, and PGE was calculated using calcusyn software. The synergistic index (CI) of the paeoniflorin and mesalazine combination was calculated based on the Dm concentration. Based on the NO determination results, the Dm of the 1:1 ratio of mesalazine to paeoniflorin was 0.025 mg / ml, which was lower than the Dm of mesalazine or paeoniflorin alone (0.035 mg / ml, 0.274 mg / ml). The synergistic index CI curve of the paeoniflorin and mesalazine combination was obtained, CI = D1 / D X1 +D2 / D X2 (where D1 and D2 are the median effective concentrations Dm of the combined action of mesalazine and paeoniflorin, D x1 、D x2 The synergistic index (CI) of mesalazine and paeoniflorin when acting alone was 0.429, and CI < 1, indicating that paeoniflorin and mesalazine had a synergistic effect; the inhibitory effect of the combination of paeoniflorin and mesalazine on COX-2 and PGE was stronger than that of either drug alone.

[0055] The technical features of the above-described embodiments can be combined arbitrarily. To make the description concise, not all possible combinations of the technical features in the above embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0056] The above-described embodiments merely illustrate several implementations of the present invention, and while their descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the present invention. It should be noted that a person skilled in the art would be able to make numerous variations and improvements without departing from the spirit of the present invention, all of which fall within the scope of protection of the present invention. Therefore, the scope of protection of the present invention shall be determined by the appended claims.

Claims

1. Use of new peony glycosides, or a combination of new peony glycosides and mesalazine in the preparation of a drug for treating inflammatory bowel disease, characterized in that: The inflammatory bowel disease is ulcerative colitis.

2. The use according to claim 1, characterized in that The drug is used to alleviate inflammation-induced colon damage.

3. The use according to claim 1, characterized in that The drug is used to inhibit colon epithelial cell pyroptosis.

4. The use according to claim 1, characterized in that The medicament is used to regulate the expression of PPAR-γ in colonic epithelium.

5. The use according to claim 1, characterized in that The drug is used to target PPAR-γ protein and activate PPAR-γ.

6. The use according to any one of claims 1 to 5, characterized in that: The drug comprises paeoniflorin and pharmaceutically acceptable excipients, the dosage of the paeoniflorin is 4 mg / kg-7 mg / kg for human administration, preferably 4.17 mg / kg-6.84 mg / kg for human administration; when paeoniflorin and mesalazine are compounded, the ratio between the two is 0.8-1.2:1, preferably 1:

1.

7. The use according to claim 6, characterized in that The dosage form of the medicine is granules, capsules, tablets, solutions, pills, and powders.

8. Peony glycosides, or a combination of paeoniflorin and mesalazine, have a synergistic effect in relieving inflammation-induced colon damage, and their use in the preparation of drugs for inhibiting colon epithelial cell pyroptosis.

9. Use of new glycosides of paeoniflorin or a combination of new glycosides of paeoniflorin and mesalazine in the preparation of a drug for regulating the expression of PPAR-γ in colon epithelium.

10. Use of new glycosides of paeoniflorin, or a combination of new glycosides of paeoniflorin and mesalazine in the preparation of a drug that targets PPAR-γ protein and activates PPAR-γ.

Citation Information

Patent Citations

  • Application of paeoniflorin in preparation of medicine for treating IV-type renal heart syndrome

    CN114767697A

  • Application of paeoniflorin in preparation of medicine for treating inflammatory bowel disease

    CN116585334A